New hope for myeloma patients: experimental drug GR1803 faces off against standard combo
NCT ID NCT07452198
First seen Apr 03, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This study tests whether a new drug called GR1803 works better than the standard combination of daratumumab, pomalidomide, and dexamethasone (DPd) for people with multiple myeloma that has returned or stopped responding after 1 to 3 prior treatments. About 358 adults will be randomly assigned to receive either GR1803 or DPd. The main goal is to see how long the cancer stays under control (progression-free survival).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.